Achieve Life Sciences, Inc. (ACHV) |
| 4.56 -0.17 (-3.59%) 02-27 16:00 |
| Open: | 4.63 |
| High: | 4.7 |
| Low: | 4.52 |
| Volume: | 193,443 |
| Market Cap: | 243(M) |
| PE Ratio: | -3.38 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.70 |
| Resistance 1: | 5.02 |
| Pivot price: | 4.34 |
| Support 1: | 3.91 |
| Support 2: | 3.25 |
| 52w High: | 6.03 |
| 52w Low: | 1.84 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Financials
| EPS | -1.350 |
| Book Value | 0.640 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -65.4 |
| Return on Equity (ttm) | -161.1 |
Company news
Wed, 25 Feb 2026
ACHV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Wed, 25 Feb 2026
Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average - What's Next? - MarketBeat
Mon, 16 Feb 2026
Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average - What's Next? - MarketBeat
Wed, 04 Feb 2026
Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch - Seeking Alpha
Mon, 02 Feb 2026
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory - Yahoo Finance
Thu, 01 Jan 2026
When Will Achieve Life Sciences, Inc. (NASDAQ:ACHV) Become Profitable? - simplywall.st
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
